J. Jefferson Smith, an officer of Precision Biosciences Inc, filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 875 shares of common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: 875 shares of Precision Biosciences common stock, with an aggregate market value of $8,955.85, according to the filing.
  • Approximate sale date: November 6, 2026, through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Shares outstanding: The filing states 27,935,719 shares of common stock were outstanding at the time of notice.
  • Original acquisition: The 875 shares were acquired on January 26, 2006, as Founders Shares from the issuer, with compensation noted as the nature of payment.
  • Prior three-month sales: The filing reports a sale of 7,056 shares on November 5, 2026, with gross proceeds of $72,411.93.
  • Rule 10b5-1 plan: The notice indicates a plan adoption date of October 10, 2025.
  • Identity clarification: The filing includes a remark stating "James J. Smith and J. Jefferson Smith are one and the same person."

Details of the Proposed Sale and Prior Transactions at Precision Biosciences

According to the Form 144 filing, J. Jefferson Smith, identified as an officer of Precision Biosciences Inc (NASDAQ:DTIL), filed a notice of proposed sale of securities on November 6, 2026. The filing discloses a proposed sale of 875 shares of the company's common stock through Fidelity Brokerage Services LLC, with an aggregate market value reported as $8,955.85. The company's address is listed as 302 East Pettigrew Street, Suite A-100, Durham, North Carolina 27701.

The filing states that the 875 shares to be sold were originally acquired on January 26, 2006, as Founders Shares from the issuer, with compensation listed as the nature of payment. The notice was submitted in reliance on a Rule 10b5-1 written trading plan adopted on October 10, 2025. The filing notes that the person signing represents they are not aware of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed, as of the plan adoption date.

In the section covering securities sold during the past three months, the filing reports that James J. Smith sold 7,056 shares on November 5, 2026, generating gross proceeds of $72,411.93. The filing includes a remark clarifying that "James J. Smith and J. Jefferson Smith are one and the same person." The notice was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for James Jefferson Smith.

What Was Disclosed

The Form 144 notice discloses an officer of Precision Biosciences Inc intends to sell 875 shares of common stock valued at $8,955.85 on NASDAQ, with the sale routed through Fidelity Brokerage Services LLC under a Rule 10b5-1 plan adopted October 10, 2025.